

ISSN 2518-1629 (Online),
ISSN 2224-5308 (Print)

ҚАЗАҚСТАН РЕСПУБЛИКАСЫ
ҰЛТТЫҚ ҒЫЛЫМ АКАДЕМИЯСЫНЫҢ
Өсімдіктердің биологиясы және биотехнологиясы институтының

Х А Б А Р Л А Р Ы

ИЗВЕСТИЯ

НАЦИОНАЛЬНОЙ АКАДЕМИИ НАУК
РЕСПУБЛИКИ КАЗАХСТАН
Института биологии и биотехнологии растений

NEWS

OF THE NATIONAL ACADEMY OF SCIENCES
OF THE REPUBLIC OF KAZAKHSTAN
of the Institute of Plant Biology and Biotechnology

**SERIES
OF BIOLOGICAL AND MEDICAL**

4 (334)

JULY – AUGUST 2019

PUBLISHED SINCE JANUARY 1963

PUBLISHED 6 TIMES A YEAR

ALMATY, NAS RK

Б а с р е д а к т о р

ҚР ҰҒА академигі, м. ғ. д., проф. **Ж. А. Арзықұлов**

Абжанов Архат, проф. (Бостон, АҚШ),
Абелев С.К., проф. (Мәскеу, Ресей),
Айтқожина Н.А., проф., академик (Қазақстан)
Ақшулақов С.К., проф., академик (Қазақстан)
Алшынбаев М.К., проф., академик (Қазақстан)
Бәтпенев Н.Д., проф., корр.-мүшесі (Қазақстан)
Березин В.Э., проф., корр.-мүшесі (Қазақстан)
Берсімбаев Р.И., проф., академик (Қазақстан)
Беркінбаев С.Ф., проф., (Қазақстан)
Бисенбаев А.К., проф., академик (Қазақстан)
Бишимбаева Н.Қ., проф., академик (Қазақстан)
Ботабекова Т.К., проф., корр.-мүшесі (Қазақстан)
Bosch Ernesto, prof. (Spain)
Давлетов Қ.К., ассоц.проф., жауапты хатшы
Жансүгірова Л.Б., б.ғ.к., проф. (Қазақстан)
Ellenbogen Adrian, prof. (Tel-Aviv, Israel),
Жамбакин Қ.Ж., проф., академик (Қазақстан), бас ред. орынбасары
Заядан Б.К., проф., корр.-мүшесі (Қазақстан)
Ishchenko Alexander, prof. (Villejuif, France)
Исаева Р.Б., проф., (Қазақстан)
Қайдарова Д.Р., проф., академик (Қазақстан)
Қохметова А.М., проф., корр.-мүшесі (Қазақстан)
Күзденбаева Р.С., проф., академик (Қазақстан)
Локшин В.Н., проф., корр.-мүшесі (Қазақстан)
Лось Д.А., prof. (Мәскеу, Ресей)
Lunenfeld Bruno, prof. (Израиль)
Макашев Е.К., проф., корр.-мүшесі (Қазақстан)
Миталипов Ш.М., (Америка)
Муминов Т.А., проф., академик (Қазақстан)
Огарь Н.П., проф., корр.-мүшесі (Қазақстан)
Омаров Р.Т., б.ғ.к., проф., (Қазақстан)
Продеус А.П., проф. (Ресей)
Purton Saul, prof. (London, UK)
Рахыпбеков Т.К., проф., корр.-мүшесі (Қазақстан)
Сапарбаев Мұрат, проф. (Париж, Франция)
Сарбасов Дос, проф. (Хьюстон, АҚШ)
Тұрысбеков Е.К., б.ғ.к., асс.проф. (Қазақстан)
Шарманов А.Т., проф. (АҚШ)

«ҚР ҰҒА Хабарлары. Биология және медициналық сериясы».

ISSN 2518-1629 (Online),

ISSN 2224-5308 (Print)

Меншіктенуші: «Қазақстан Республикасының Ұлттық ғылым академиясы» РҚБ (Алматы қ.)

Қазақстан республикасының Мәдениет пен ақпарат министрлігінің Ақпарат және мұрағат комитетінде
01.06.2006 ж. берілген №5546-Ж мерзімдік басылым тіркеуіне қойылу туралы куәлік

Мерзімділігі: жылына 6 рет.

Тиражы: 300 дана.

Редакцияның мекенжайы: 050010, Алматы қ., Шевченко көш., 28, 219 бөл., 220, тел.: 272-13-19, 272-13-18,
<http://biological-medical.kz/index.php/en/>

© Қазақстан Республикасының Ұлттық ғылым академиясы, 2019

Типографияның мекенжайы: «Аруна» ЖК, Алматы қ., Мұратбаева көш., 75.

Г л а в н ы й р е д а к т о р

академик НАН РК, д.м.н., проф. **Ж. А. Арзыкулов**

Абжанов Архат, проф. (Бостон, США),
Абелев С.К., проф. (Москва, Россия),
Айтхожина Н.А., проф., академик (Казахстан)
Акшулаков С.К., проф., академик (Казахстан)
Алчинбаев М.К., проф., академик (Казахстан)
Батпенов Н.Д., проф. член-корр.НАН РК (Казахстан)
Березин В.Э., проф., чл.-корр. (Казахстан)
Берсимбаев Р.И., проф., академик (Казахстан)
Беркинбаев С.Ф., проф. (Казахстан)
Бисенбаев А.К., проф., академик (Казахстан)
Бишимбаева Н.К., проф., академик (Казахстан)
Ботабекова Т.К., проф., чл.-корр. (Казахстан)
Bosch Ernesto, prof. (Spain)
Давлетов К.К., ассоц. проф., ответственный секретарь
Джансугурова Л. Б., к.б.н., проф. (Казахстан)
Ellenbogen Adrian, prof. (Tel-Aviv, Israel),
Жамбакин К.Ж., проф., академик (Казахстан), зам. гл. ред.
Заядан Б.К., проф., чл.-корр. (Казахстан)
Ishchenko Alexander, prof. (Villejuif, France)
Исаева Р.Б., проф. (Казахстан)
Кайдарова Д.Р., проф., академик (Казахстан)
Кохметова А.М., проф., чл.-корр. (Казахстан)
Кузденбаева Р.С., проф., академик (Казахстан)
Локшин В.Н., проф., чл.-корр. (Казахстан)
Лось Д.А., prof. (Москва, Россия)
Lunenfeld Bruno, prof. (Израиль)
Макашев Е.К., проф., чл.-корр. (Казахстан)
Миталипов Ш.М., (Америка)
Муминов Т.А., проф., академик (Казахстан)
Огарь Н.П., проф., чл.-корр. (Казахстан)
Омаров Р.Т., к.б.н., проф. (Казахстан)
Продеус А.П., проф. (Россия)
Purton Saul, prof. (London, UK)
Рахыпбеков Т.К., проф., чл.-корр. (Казахстан)
Сапарбаев Мурат, проф. (Париж, Франция)
Сарбасов Дос, проф. (Хьюстон, США)
Турысбеков Е. К., к.б.н., асс.проф. (Казахстан)
Шарманов А.Т., проф. (США)

«Известия НАН РК. Серия биологическая и медицинская».

ISSN 2518-1629 (Online),

ISSN 2224-5308 (Print)

Собственник: РОО «Национальная академия наук Республики Казахстан» (г. Алматы)

Свидетельство о постановке на учет периодического печатного издания в Комитете информации и архивов Министерства культуры и информации Республики Казахстан №5546-Ж, выданное 01.06.2006 г.

Периодичность: 6 раз в год

Тираж: 300 экземпляров

Адрес редакции: 050010, г. Алматы, ул. Шевченко, 28, ком. 219, 220, тел. 272-13-19, 272-13-18,

www.nauka-nanrk.kz / biological-medical.kz

© Национальная академия наук Республики Казахстан, 2019

Адрес типографии: ИП «Аруна», г. Алматы, ул. Муратбаева, 75

Editor in chief

Zh.A. Arzykulov, academician of NAS RK, Dr. med., prof.

Abzhanov Arkhat, prof. (Boston, USA),
Abelev S.K., prof. (Moscow, Russia),
Aitkhozhina N.A., prof., academician (Kazakhstan)
Akshulakov S.K., prof., academician (Kazakhstan)
Alchinbayev M.K., prof., academician (Kazakhstan)
Batpenov N.D., prof., corr. member (Kazakhstan)
Berezin V.Ye., prof., corr. member. (Kazakhstan)
Bersimbayev R.I., prof., academician (Kazakhstan)
Berkinbaev S.F., prof. (Kazakhstan)
Bisenbayev A.K., prof., academician (Kazakhstan)
Bishimbayeva N.K., prof., academician (Kazakhstan)
Botabekova T.K., prof., corr. member. (Kazakhstan)
Bosch Ernesto, prof. (Spain)
Davletov Kairat, PhD, associate professor, executive Secretary
Dzhansugurova L.B., Cand. biol., prof. (Kazakhstan)
Ellenbogen Adrian, prof. (Tel-Aviv, Israel),
Zhambakin K.Zh., prof., academician (Kazakhstan), deputy editor-in-chief
Ishchenko Alexander, prof. (Villejuif, France)
Isayeva R.B., prof. (Kazakhstan)
Kaydarova D.R., prof., academician (Kazakhstan)
Kokhmetova A., prof., corr. member (Kazakhstan)
Kuzdenbayeva R.S., prof., academician (Kazakhstan)
Lokshin V.N., prof., corr. member (Kazakhstan)
Los D.A., prof. (Moscow, Russia)
Lunefeld Bruno, prof. (Israel)
Makashev E.K., prof., corr. member (Kazakhstan)
Mitalipov Sh.M. (America)
Muminov T.A., prof., academician (Kazakhstan)
Ogar N.P., prof., corr. member (Kazakhstan)
Omarov R.T., cand. biol., prof. (Kazakhstan)
Prodeus A.P., prof. (Russia)
Purton Saul, prof. (London, UK)
Rakhypbekov T.K., prof., corr. member. (Kazakhstan)
Saparbayev Murat, prof. (Paris, France)
Sarbassov Dos, prof. (Houston, USA)
Turysbekov E.K., cand. biol., assoc. prof. (Kazakhstan)
Sharmanov A.T., prof. (USA)

News of the National Academy of Sciences of the Republic of Kazakhstan. Series of biology and medicine.

ISSN 2518-1629 (Online),

ISSN 2224-5308 (Print)

Owner: RPA "National Academy of Sciences of the Republic of Kazakhstan" (Almaty)

The certificate of registration of a periodic printed publication in the Committee of information and archives of the Ministry of culture and information of the Republic of Kazakhstan N 5546-Ж, issued 01.06.2006

Periodicity: 6 times a year

Circulation: 300 copies

Editorial address: 28, Shevchenko str., of. 219, 220, Almaty, 050010, tel. 272-13-19, 272-13-18,
<http://nauka-nanrk.kz / biological-medical.kz>

© National Academy of Sciences of the Republic of Kazakhstan, 2019

Address of printing house: ST "Aruna", 75, Muratbayev str, Almaty

NEWS

OF THE NATIONAL ACADEMY OF SCIENCES OF THE REPUBLIC OF KAZAKHSTAN

SERIES OF BIOLOGICAL AND MEDICAL

ISSN 2224-5308

Volume 4, Number 334 (2019), 27 – 34

<https://doi.org/10.32014/2019.2519-1629.36>

UDC 577.21, 616.127-005.8

O. Yu. Yurikova¹, Sh. A. Atambaeva¹, A. A. Bolshoy², A. T. Ivashchenko¹¹Scientific research institute of biology and biotechnology problems, al-Farabi Kazakh national university, Almaty, Kazakhstan,²Department of Evolutionary and Environmental Biology, University of Haifa, Haifa, Israel.

E-mail: oksanayurikova@mail.ru, atambayevashara@gmail.com,

bolshoy@research.haifa.ac.il, a.iavashchenko@gmail.com

**FEATURES OF THE BINDING OF miR-1322 WITH mRNAs
OF GENES ENCODING POLYGLUTAMINE-CONTAINING PROTEINS**

Abstract. Many genes encode proteins containing polyglutamine tract, which function is not studied well. It has been established that polyglutamine expansion causes some diseases. Using the MirTarget program, we found that nucleotide sequences in the mRNA of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A* and *POLG* genes are miR-1322 binding sites. This miRNA can bind with the sites in mRNA and suppress genes expression. There are 22, 16, 8, 17, 9 and 9 miR-1322 binding sites in mRNAs of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A*, *POLG* genes, respectively. These polysites encode polyglutamine from 10 to 29 amino acid residues in length. Most of the studied proteins are transcription factors and inhibition of their synthesis can cause neurodegenerative, cardiovascular and oncological diseases. MiRNA binding sites in mRNAs of orthologues genes indicate the emergence of regulation of the studied genes expression by miR-1322 many millions of years ago. Animals containing miR-1322 target genes can serve as experimental models to study the role of polyglutamine in the development of diseases.

Keywords: miR-1322, mRNA, gene, polyglutamine, disease.

Introduction. miRNAs are small non-coding RNAs that are able to regulate gene expression at post transcription level by binding with mRNAs. The role of miRNAs in different biological processes is actively being investigated. It has been shown that these molecules can act as intracellular and intercellular signaling regulators. It has been established that miRNAs bind to mRNAs in 3'-untranslated regions (3'UTRs), 5'-untranslated regions (5'UTRs) and coding domain sequences (CDSs) [1, 2]. Moreover, some miRNAs have binding sites (BS) in 5'UTRs, CDSs, and 3'UTRs [3]. The efficacy of miRNA-mediated repression increased with the number of sites [4]. It is assumed that miRNA binding to mRNA can be significant if the gene contains repeats of site sequences in coding region. Bioinformatics is actively used to fully understand, manage and analyze biological data [5]. It is possible to predict interactions between miRNAs and mRNAs and their properties by using different programs [6]. It has been shown that among 17,494 mRNA sequences of human genes miR-1322 has BS in 1,058 genes [7]. Most of them are located in repeat-rich coding regions of mRNAs. Depending on reading frames these BS encode polyGlu, polyAla or polySer. The objective of this study is to research the properties of miR-1322 BS in mRNAs of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A* and *POLG* and their orthologues. These genes are involved in several diseases. Cytosine-adenine-guanine (CAG) repeat expansions in the coding regions of *ATXN1*, *ATXN2*, and *ATXN7* are the cause of spinocerebellar ataxias (SCAs) [8]. It has been shown that *KCNN3* may play an important role in the pathogenesis of atrial fibrillation [9]. In other study the *KCNN3* and other small conductance calcium-activated potassium channels are proposed as promising therapeutic targets for neurodegenerative disorders such as Parkinson's disease [10] It has been shown that *MEF2A* might be involved in myocardial infarction, neurodegenerative disorders and in hepatocellular carcinoma development [11, 12]. It has been shown that *POLG* can play a significant role in Parkinson's disease and tumor promotion [13, 14]. Studying of regulation mechanisms of these genes expression is a

promising area for detection and treatment of some neurodegenerative, cardiovascular and oncological diseases.

Materials and methods. The nucleotide sequences of mRNAs of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A* and *POLG* human genes (Homo sapiens – *Hsa*) and their orthologous genes (*Acinonyx jubatus* – *Aju*, *Ailuropoda melanoleuca* – *Ame*, *Balaenoptera acutorostrata scammoni* – *Bac*, *Bos mutus* – *Bmu*, *Bos taurus* – *Bta*, *Castor Canadensis* – *cca*, *Callithrix jacchus* – *Cja*, *Canis familiaris* – *Cfa*, *Capra hircus* – *Chi*, *Chlorocebus sabaues* – *Csa*, *Cricetulus griseus* – *Cgr*, *Equus caballus* – *Eca*, *Felis catus* – *Fca*, *Gorilla gorilla* – *Ggo*, *Loxodonta africana* – *Laf*, *Lipotes vexillifer* – *Lve*, *Macaca fascicularis* – *Mfa*, *Macaca mulatta* – *Mml*, *Monodelphis domestica* – *Mdo*, *Mus musculus* – *Mmu*, *Nannospalax galili* – *Nga*, *Nomascus leucogenys* – *Nle*, *Ornithorhynchus anatinus* – *oan*, *Oryctolagus cuniculus* – *Ocu*, *Ovis aries* – *Oar*, *Pan paniscus* – *Ppa*, *Pan troglodytes* – *Ptr*, *Pteropus alecto* – *Pal*, *Pongo abelii* – *Pab*, *Pantholops hodgsonii* – *Pho*, *Rhinopithecus bieti* – *Rbi*, *Rhinopithecus roxellana* – *Rro*, *Rattus norvegicus* – *Rno*, *Saimiri boliviensis boliviensis* – *Sbo*, *Sarcophilus harrisii* – *sha*, *Sus scrofa* – *Ssc*) were downloaded from NCBI GenBank (<http://www.ncbi.nlm.nih.gov>). Nucleotide sequence of human mature miR-1322 was downloaded from the miRBase database (<http://mir-base.org>). The miR-1322 binding sites in CDS region of mRNAs of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A*, *POLG* genes were predicted using the MirTarget program. This program defines the features of binding: a) the localization of miRNA BS in 5'UTR, CDS and 3'UTR of mRNAs; b) the free energy of hybridization (ΔG , kJ/mole); c) schemes of nucleotide interactions between miRNAs and mRNA. The ratio $\Delta G/\Delta G_m$ (%) was determined for each site (ΔG_m equals the free energy of miRNA binding with its perfect complementary nucleotide sequence). miRNA BS interacting with mRNAs with $\Delta G/\Delta G_m$ ratio of 85% or more were considered. Described BS are polysites arranged in series. The program determines position of BS beginning from the first nucleotide of 5'UTR mRNA. The MirTarget program also takes into account the hydrogen bonds between adenine (A) and uracil (U), guanine (G) and cytosine (C), G and U; A and C [3].

Results and discussion. Using MirTarget program, miR-1322 binding polysites in CDS region of mRNAs of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A*, *POLG* genes were detected. mRNAs and miR-1322 interaction characteristics are given in the table 1. Free energy of hybridization (ΔG) of miR-1322 with mRNAs of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A*, *POLG* genes is within -87÷-93 kJ/mole. Probability of the interaction between mRNA and miRNA is increases with the increase in length of polysites. $\Delta G/\Delta G_m$ of miR-1322 binding polysites ranged from 85 to 92%.

Table 1 – Characteristics of miR-1322 polysites in mRNAs of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A*, *POLG* genes

Gene	The position of the beginning of binding site, nt	$\Delta G/\Delta G_m$, %	Oligopeptides
<i>ATXN1</i>	1559 - 1592 (12) 1604 - 1631 (10)	85.4 ÷ 91.7 87.5 ÷ 89.6	QQQQQQQQQQQQHQHQQQ QQQQQQQQQQQQQH
<i>ATXN2</i>	657 - 714 (16)	87.5 ÷ 89.6	QQQQQQQQQQQQQQQQQQQQQQQQPP
<i>ATXN7</i>	637 - 658 (8)	85.4 ÷ 89.6	QQQQQQQQQQPP
<i>KCNN3</i>	401- 425 (7) 512 - 539 (10)	87.5 ÷ 91.7 87.5 ÷ 91.7	QQQQQQQQQQQQPP QQQQQQQQQQQQQP
<i>MEF2A</i>	1836 - 1860 (9)	85.4 ÷ 89.6	GFQQQQQQQQQQQP
<i>POLG</i>	405 - 428 (9)	85.4 ÷ 87.5	RQQQQQQQQQQQQQPQ

Expansion of a polyglutamine tract within the *ATXN1* causes lethal neurodegenerative disorder SCA1 [15]. Understanding the normal function of *ATXN1* is essential to decipher the pathogenesis mechanisms in SCA1. Normal alleles of *ATXN1* have a size range of 19–36 repeats, whereas pathological alleles have 39–82 repeats. Two clusters of miR-1322 polysites have been predicted in CDS of mRNA of *ATXN1*: 12 BS for miR-1322 at the position from 1559 to 1611 and 10 miR-1322 BS from 1604 to 1650 nucleotides, respectively. The region of *ATXN1*, which contains miR-1322 binding is flanked by conserved oligopeptides in a number of orthologs (table 2). $\Delta G/\Delta G_m$ value of miR-1322 interaction with the mRNA BS of *ATXN1* is in the range of 85 to 92%. All orthologs in mRNA of *ATXN1* have a decrease

Table 2 – Oligopeptides of orthologous ATXN1 proteins encoded by miR-1322 binding sites

LSQTPGHKAE QQQQQQQQQQQQQHQQQQQQQQQQQQQH LSRAPGLITP	<i>Hsa</i>
LSQTPGHKAE QQQQQQQQQQQQQHQQQQQQQQQQQH ...LSRAPGLITP	<i>Ppa</i>
LSQTPGHKAE QQQQQHQQQQQQQHQQQQQQQQQH ...LSRAPGLITP	<i>Pab</i>
LSQTPGHKAE QQQQQQQQQQQHQQQQQQQQQQQH ...LSRAPGLITP	<i>Ptr</i>
LSQTPGHKAE QQQQQQQQQQQQQQQH ...LSRAPGLITP	<i>Mfa</i>
LSQTPGHKAE QQQQQQQQQQQQQQQH ...LSRAPGLITP	<i>Mml</i>
LSQTPGHKAE QQQQQQQQQQQQQQQH ...LSRAPGLITP	<i>Nle</i>
LSQTPGHKAE QQQQQQQQQQQQHHH ...LSRAPGLITP	<i>Rro</i>
LSQTPGHKAE QQQQQQQQQQQQQH ...LSRAPGLITP	<i>Ggo</i>
LSQTPGHKAE QQQQQQQQQQQQHH ...LSRAPGLITP	<i>Csa</i>

Note: in the Table 2 and hereinafter the bold type indicates amino acids encoded by miR-1322 binding sites

in the number of miR-1322 BS (table 2). Most orthologues mRNAs containing miR-1322 BS were revealed among primates and contained only first set of two miR-1322 polysites.

The protein encoded by the *ATXN2*, contains a polyglutamine tract, long expansion (greater than 33 repeats) of which result in SCA2. Intermediate-length expansions (27-33 glutamines) contribute to susceptibility to amyotrophic lateral sclerosis [16]. In CDS mRNA of *ATXN2* gene, 16 miR-1322 BS were identified in the region from 657 to 733 nucleotides of mRNA with an interaction value $\Delta G/\Delta G_m$ of 87.5-89.6%. The region of mRNA of *ATXN2*, which contains miR-1322 BS in CDS, encodes polyGlu. For the group of orthologues, polyGlu in *ATXN2* protein is flanked by conservative decapeptides (table 3). Most species of *ATXN2* gene orthologs in mRNA contains decrease in the number of miR-1322 BS, except *P. troglodytes* containing 19 miR-1322 BS. *F. catus*, *N. leucogenys* have only five amino acids in *ATXN2* protein sequences before polyglutamine tract. While studying the regulation of *ATXN2* expression by miR-1322 in mammals, difference in the number of miR-1322 polysites in mRNA of *ATXN2* gene orthologs should be taken into account.

Table 3 – Oligopeptides of orthologous ATXN2 proteins encoded by miR-1322 binding sites

YGPLTMSLKP QQQQQQQQQQQQQQQQQQQQQQQQQQQQPP PAAANVRKPG	<i>Ptr</i>
YGPLTMSLKP QQQQQQQQQQQQQQQQQQQQQQQQQQPP ...PAAANVRKPG	<i>Hsa</i>
...MSLKP QQQQQQQQQQQQQQQQQQQQQQPP ...PPAAANVRKPG	<i>Nle</i>
YGPLTMSLKP QQQQQQQQQQQQQQQQQQPP ...PPAAANVRKPG	<i>Csa</i>
YGPLTMSLKP QQQQQQQQQQQQQQQQPP ...AAANVRKPG	<i>Mml, Mfa</i>
YGPLTMSLKP QQQQQQQQQQQQQQPP ...AAANVRKPG	<i>Cja</i>
YGPLTMSLKP QQQQQQQQPPQP ...AAANARKPG	<i>Bta</i>
YGPLTMSLKP QQQQQQQQPPQP ...AAANARKPG	<i>Chi</i>
...MSLKP QQQQQQQQPP ...AAANARKPG	<i>Fca</i>
YGPLTMSLKP QQQQQQQQPP ...AAANARKPG	<i>Aju</i>

ATXN7 is a transcription factor that appears to be critically important for chromatin remodeling at the level of histone acetylation and deubiquitination [17]. It has been determined that the diseased allele associated with SCA7 contains 37-306 CAG, compared to 4-35 in the normal allele [18]. mRNA of *ATXN7* contains eight miR-1322 BS with $\Delta G/\Delta G_m$ ratio of 85 to 90%. miR-1322 BS are found in 12 mammalian species mRNAs of *ATXN7* orthologs (table 4). mRNA of human *ATXN7* contains the greatest number of miR-1322 BS. A decrease in the number of miR-1322 BS in mRNAs of orthologs was observed. So, there are seven miR-1322 BS in mRNA of *O. cuniculus*, six miR-1322 BS in mRNA of *P. abelii* and *Ch. sabaesus*, Five miR-1322 BS are predicted in mRNA of *M. musculus*, Variable in length polyalanine sequence flanks polyGlu from the N-terminal in *ATXN7* protein. Amino acid sequence flanking the BS from C-terminus of *ATXN7* is also variable in orthologous proteins.

Table 4 – Oligopeptides of orthologous ATXN7 proteins encoded by miR-1322 binding sites

RAAAA . GGAAAAAAR QQQQQQQQQQPP PPQPQRQQHPPPPRR	<i>Hsa</i>
RAAAAAGGAAAA . . RQPQQQQQQPP . . . QPQRQQ . . . PPRR	<i>Ocu</i>
RAAAAAGGAAAAAAR QQQQQQQQPP . . . SQPQRQP PPPPPPPRR	<i>Cfa</i>
RAAAAAGGAAAAAAR QQQQQQQP SQPQRQHSPPPPRR	<i>Cja</i>
RAAAAAGGAAAAAAR QQQQQQQP QPQRQQQPPPPRR	<i>Pab</i>
RAAAA . GGAAAAAAR QQQQQQQP QPQRQQQPPPPPR	<i>Csa</i>
RRAA . . GGAAAA . . RQQQQQPQP LQPQRQHPL . . . RR	<i>Mmu</i>
RAAAAAGGAAAAAG RQQQQQP QSQRQQQPPPPRR	<i>Nle</i>
RAAAAGGAAAAAAR RQQQQQP QPQRQQQPPPPPR	<i>Mml</i>
RAAAAAGGAAAAAAR QQQQQP QPQRQ . . PPP . RR	<i>Chi</i>
RAAAA . GGAAAAAAR QQQQQP QPPQPQRQPPP . RR	<i>Ssc</i>
RRAA . . GGAAAA . . RQQQPQP LQLQRQ . . HPPP . RR	<i>Rno</i>

KCNN3 belongs to the *KCNN* family of potassium channels and contains two CAG repeat regions in CDS. It has been shown that *KCNN3* SNP polymorphism significantly increases the risk of atrial fibrillation [19]. SK channels are promising therapeutic targets for Parkinson's disease [9]. It has been established that both polyGlu regions are encoded by miR-1322 BS. These two sets of polysites consist of seven and ten BS ($\Delta G/\Delta G_m$ is equal to 87.5 – 91.7%) located in *KCNN3* mRNA from 401 to 444 nt and from 512 to 558 nt, respectively (table 5, 6).

Table 5 – Oligopeptides of orthologous *KCNN3* proteins encoded by miR-1322 binding sites located from 401 to 444 nt

KCPCPSSGDE QQQQQQQQQQQQQQQQPP PPPAPPATPQQPPGPPL	<i>Laf</i>
KCPCPSSGDE QQQQQQQQQQQQQQQQPP . . PPAPPAAPQQPLGPSL	<i>Ggo</i>
KCPCPSSGDE QQQQQQQQQQQQQQQP PPAPPAAPQQPLGPSL	<i>Ptr</i>
KCPCPSSGDE QQQQQQQQQQQQQP PPAPPAAPQQPLGPSL	<i>Hsa</i>
KCPCPSSGDE QQQQQQQQQQQQQP PPAPPAAPQQPLGPSL	<i>Pab</i>
KCPCPSSGDE QQQQQQQQQQQP PPAPPAAPQQPLGPSL	<i>Mml</i>
KCPCPSSGDE QQQQQQQQQQQP PPAPPAAPQQPLGPSL	<i>Mfa</i>
KCPCPSSGDE QQQQQQQQQQQP PPAPPAAPQQPLGPSL	<i>Csa</i>
KCPCPSSGDE QQQQQQQQQQQP PPAPPAAPQQPLGPSL	<i>Nle</i>
KCPCPSSGDE QQQQQQQQQQQP PPPPAPPAAPQQPPGPQ	<i>Eca</i>
KCPCPSSGDE QQQQQQQQQQQP PPPPAPPAAPQQPPGPSL	<i>Sbo</i>
KCPCPSSGDE QQQQQQQQQP PPPPAPPAAPQQPPGPSL	<i>Cja</i>
KCPCPSSGDE QQQQQQQP PPPPAPPAAPQQPPGPPL	<i>Bta</i>
KCPCPSSGDE QQQQQP PPPAPPAAPQQPPGPLL	<i>Nga</i>
KCPCPSSGDE QQQQQP PPSAPPAVPQQPPGPLL	<i>Rno</i>
KCPCPSSGDE QQQQQP PPPAPPAVPQQPPGPLL	<i>Mmu</i>

The change in the number of miR-1322 BS was identified in both GAU repeat-rich sequences of *KCNN3* mRNA. The increase in the first miR-1322 binding polysites was revealed in orthologues *KCNN3* mRNAs of *L. africana*, *G. gorilla*, *P. troglodytes*. The identical number of miR-1322 BS has been found in mRNAs of *P. abelii* and *H. sapiens*. The greatest number of second miR-1322 binding polysites among orthologs was found in mRNAs of *N. galili* and *P. troglodytes*. Oligopeptides flanking polyGlu sequence encoded by miRNA BS are quite conserved in many mammalian species; however, there are changes in length of polyproline sequences flanking first set of polyGlu from C-terminus of *KCNN3*.

Table 6 – Oligopeptides of orthologous KCNN3 proteins encoded by miR-1322 binding sites located from 512 to 558 nt

GPLLQPQPPQL QQQ QQQQQQQQQQQQQQQQQQQQ Q PHPLSQLAQL	<i>Nga</i>
GPSLQPQPPQL QQQ QQQQQQQQQQQQQQQQQQQQ Q PHPLSQLAQL	<i>Ptr</i>
GPSLQPQPPQL QQQ QQQQQQQQQQQQQQQQQQQQ Q PHPLSQLAQL	<i>Mml, Mfa</i>
GPLLQPQPPQL QQQ QQQQQQQQQQQQQQQQQQQQ Q APLHPLPQLAQL	<i>Rno</i>
GPLLQPQPPQL QQQ Q S QQQQQQQQ S QQQQQQ Q APLHPLPQLAQL	<i>Mmu</i>
GPSLQPQPPQL QQQ QQQQQQQQQQQQQQQQQQQQ Q PHPLSQLAQL	<i>Ggo</i>
GPSLQPQPPQL QQQ QQQQQQQQQQQQQQQQQQQQ Q PHPLSQLAQL	<i>Hsa</i>
GPSLQPQPPQL QQQ QQQQQQQQQQQQQQQQQQQQ Q PHPLSQLAQL	<i>Pab</i>
GPPLQPQPPQL QQQ QQQQQQQQQQQQQQQQQQQQ Q HPLSQLAQL	<i>Lve</i>
GPSLQPQPPQL QQQ QQQQQQQQQQQQQQQQQQQQ Q PHPLSQLAQL	<i>Csa</i>
GPPLQPQPLQL QQQ QQQQQQQQQQQQQQQQQQQQ Q PHPLSQLAQL	<i>Ssc</i>
GPPLQPQPPQL QQQ QQQQQQQQ Q PHPLSQLAQL	<i>Bac, Eca</i>
GPPLQPQPPQL QQQ QQQQ Q PHPLSQLTQL	<i>Bmu</i>
GPSLQPQPPQL QQQ QQQQ X PHPLSQLAQL	<i>Sbo</i>
GPPLQPQPPQL QQQ QQQQ Q PHPLSQLTQL	<i>Oar, Bta, Chi</i>
GPSLQPQPPQL QQQ QQQQ Q PHPLSQLAQL	<i>Nle, Cja</i>
GPPLQPQPPQL Q QQQQ Q PHPLSQLSQ	<i>Laf</i>

The protein encoded by *MEF2A* gene is a DNA-binding transcription factor of MEF2 family. *MEF2A* protects primary neurons from oxidative stress-induced cell damage and may be involved in various neurodegenerative-related diseases [20]. *MEF2A* is associated with myocardial infarction [21]. Overexpression of *MEF2A* is associated with hepatocellular carcinoma [22]. There are nine miR-1322 BS located in CDS of mRNA of *MEF2A* with $\Delta G/\Delta G_m$ of 85.4 to 89.6%. polyGlu encoded by miR-1322 BS are flanking by conserved oligopeptides PRDRMTPS from N-terminus and RQEMGRSPVDS from C-terminus of *MEF2A* (table 7).

Table 7 – Oligopeptides of orthologous MEF2A proteins encoded by miR-1322 binding sites

PRDRMTPS GF QQQQQQQQQQQQQQQQQQQQQQ Q ARQEMGRSPVDS	<i>Sha</i>
PRDRMTPS GF PQQQQQQQQQQQQQQQQQQQQ Q SSRQEIGRSPVDS	<i>Oan</i>
PRDRMTPS GF PQQQQQQQQQQQQQQQQQQQQQQ Q ARQEMGRSPVDS	<i>Mdo</i>
PRDRMTPS GF QQQQQQQQQQQQQQQQQQQQQQ Q PPPPPPPQPPQPQPRQEMGRSPVDS	<i>Nga</i>
PRDRMTPS GF QQQQQQQQQQQQQQQQQQQQ Q PPPPPPPQPPQPQPRQEMGRSPVDS	<i>Rro</i>
PRDRMTPS GF QQQQPPQQQQQQQQ Q PPPPPPPQPPQPQPRQEMGRSPVDS	<i>Nle</i>
PRDRMTPS GF QQQQQQQQQQQQ S QPPPPPPPQPPQPQPRQEMGRSPVDS	<i>Eca</i>
PRDRMTPS GF QQQQQQQQQQQQ Q PPPPPPPQPPQPQPRQEMGRSPVDS	<i>Hsa</i>
PRDRMTPS GF QQQQQQQQQQQQ Q PPPPPPPQPPQPQPRQEMGRSPVDS	<i>Cgr</i>
PRDRMTPS GF QQQQQQQQQQ Q PPPPPPPQPPQPQPRQEMGRSPVDS	<i>Sbo</i>
PRDRMTPS GF QQQQQQ Q PPPPPPPQPPQPQPRQEMGRSPVDS	<i>Mmu</i>

However, there are variable amino acid sequences containing proline and glutamine residues between polyGlu and RQEMGRSPVDSL. The maximum number of miR-1322 BS among *MEF2A* orthologues were found in *S. harrisii* (22), *O. anatinus* (22), *M. domestica* (21). *M. musculus* has 8 BS for miR-1322 in mRNA of *MEF2A* that should be taken into account while studying the regulation of *MEF2A* expression by miR-1322 using *M. musculus*.

The protein encoded by *POLG* is the catalytic subunit of mitochondrial DNA polymerase. *POLG* contains a polyglutamine tract. Nine miR-1322 BS were found in mRNA of *POLG*. This region encodes polyGlu sequence in the protein. The miR-1322 BS are located from 205 to 227 nt in *POLG* mRNA, $\Delta G/\Delta G_m$ is equal to 85.4 – 87.5%. There is a decrease in number of miR-1322 polysites among *POLG*

Table 8 – Oligopeptides of orthologous POLG proteins encoded by miR-1322 binding sites

SSSVPASDPSDGQRR.R QQQQQQQQQQQQQQQPQQP QVLSSEGGQL	<i>Hsa</i>
SSSVPASDPSDGQRRR QQQQQQQQQQPQQPQ .QPQVLSSEGGQL	<i>Ggo</i>
SSSVPASDPSDGQRRR QQQQQQQQPQQPQ ...QPQVLSSEGGQP	<i>Ptr</i>
SSSVPASDPSDG.RR.R QQQQQQQQQQPQ ...QPQVPSSEGGQL	<i>Nle</i>
SSSVPASDPSDGQRR.R QQQQQQQQQPQ ...QPQVLSSEGGQL	<i>Ppa</i>
SSSVPASDPSDEQRRR QQQQQQQQQPQ ...QPQVPSSEGGQL	<i>Pab</i>
SSSVPASDPSDG.RRR QQQQQQQQQPQ ...QPQVPSSEGGQL	<i>Rbi</i>
SSSVPASDPSDG.RRR QQQPQQQPQVPSSEGGQL	<i>Rro</i>

orthologues. It was identified that miR-1322 polysites exist in *POLG* mRNA in *G. gorilla*, *P. troglodytes*, *N. leucogenys*, *P. paniscus*, *P. abelii*, *R. bieti* and *R. roxellana*. Therefore, in further studying of regulation of *POLG* expression by miR-1322 only some animals could be used as experimental model.

Conclusion. miR-1322 BS were found in mRNAs of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A* and *POLG*. These binding sites are identified to encode polyGlu. in the orthologous proteins of studied animal species. The number of polyGlu amino acid residues varies during the evolution of species and it was established a tendency of increasing in the length of polyGlu sequence in the proteins during evolution. *In vitro* experiments and clinical research are needed to be conducted for further validation of the interaction between miR-1322 and mRNAs of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A* and *POLG*. The obtained results demonstrate the possibility of an involvement of miR-1322 in diseases caused by these genes. Our analysis of physicochemical properties of BS allows us to propose an adequate experimental animal for study of regulation of *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A* and *POLG* expression by miR-1322.

Funding. The study was carried out with financial support of the Ministry of Education and Science of the Republic of Kazakhstan within the framework of grant.

О. Ю. Юрикова¹, Ш. А. Атамбаева¹, А. А. Большой², А. Т. Ивашенко¹

¹Биология және биотехнология мәселелерінің ғылыми-зерттеу институты, әл-Фараби атындағы Қазақ ұлттық университеті, Алматы, Қазақстан,

²Хайфа университетінің эволюциялық және экологиялық биология кафедрасы, Хайфа, Израиль

MIR-1322 ЖӘНЕ ПОЛИГЛУТАМИНІ БАР АҚУЫЗДАРДЫ КОДТАЙТЫН ГЕНДЕРДІҢ АРАСЫНДАҒЫ БАЙЛАНЫСУ САЙТТАРДЫҢ ЕРЕКШЕЛІКТЕРІ

Аннотация. Көптеген гендер полиглутаминдік тракті бар ақуыздарды кодтайды, олардың қызметі толық анықталмаған. Ұзын полиглутаминдік тізбектің синтезі кейбір аурулардың себебі болып табылатынын көрсетілген. MirTarget бағдарламасын пайдалана отырып, *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A* және *POLG* гендерінің mRNA-ындағы нуклеотидтік тізбектер miR-1322-ның байланысу сайттары екендігі анықталды. Бұл miRNA mRNA-рымен байланыса алады және геннің экспрессиясын тежейді. *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A*, *POLG* гендердің mRNA-сында 22, 16, 8, 17, 9 және 9 miR-1322 байланысу сайттары бар. Бұл полисайттар, ұзындығы 10-29 амин қышқылдық қалдықтарынан тұратын, полиглутаминді кодтайды. Зерттелген ақуыздардың көпшілігі транскрипциялық факторлар болып табылады, және олардың синтезінің тежеуі нейродегенеративті, жүрек-тамыр және онкологиялық ауруларға алып келуі мүмкін. Ортологиялық гендердің мРНК-да miR-1322 байланысу сайттардың болуы, зерттелген гендердің экспрессиясын реттеуінің миллиондаған жылдар бұрын пайда болғанын көрсетеді. МиР-1322-ның нысана-гендері бар жануарлар, аурулардың дамуындағы полиглутаминнің рөлін зерттеу үшін, тәжірибелік модель ретінде болуы мүмкін.

Түйін сөздер: miR-1322, mRNA, ген, полиглутамин, ауру.

О. Ю. Юрикова¹, Ш. А. Атамбаева¹, А. А. Большой², А. Т. Ивашенко¹

¹НИИ Проблем биологии и биотехнологии

Казахского национального университета им. аль-Фараби, Алматы, Казахстан,

²Кафедра эволюционной и экологической биологии, Хайфский университет, Хайфа, Израиль

ОСОБЕННОСТИ САЙТОВ СВЯЗЫВАНИЯ miR-1322 С ГЕНАМИ, КОДИРУЮЩИМИ ПОЛИГЛУТАМИН-СОДЕРЖАЩИЕ БЕЛКИ

Аннотация. Многие гены кодируют белки, содержащие полиглутаминовый тракт, функция которого до конца не изучена. Было показано, что синтез удлинённой последовательности полиглутаминина является причиной некоторых заболеваний. С помощью программы MirTarget нами было обнаружено, что нуклеотидные последовательности в мРНК генов *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A* и *POLG* являются сайтами связывания miR-1322. Эта miRNA может связываться с сайтами в mRNA и подавлять экспрессию генов. В mRNAs генов *ATXN1*, *ATXN2*, *ATXN7*, *KCNN3*, *MEF2A*, *POLG* содержатся соответственно 22, 16, 8, 17, 9 и 9 сайтов связывания miR-1322. Эти полисайты кодируют полиглутамин длиной от 10 до 29 аминокислотных остатков. Большинство изученных белков являются транскрипционными факторами, и ингибирование их синтеза может вызывать нейродегенеративные, сердечно-сосудистые и онкологические заболевания. Наличие сайтов связывания miR-1322 в mRNA ортологических генов указывают на возникновение регуляции экспрессии изученных генов много миллионов лет назад. Животные, содержащие гены-мишени miR-1322, могут служить в качестве экспериментальных моделей для изучения роли полиглутаминина в развитии заболеваний.

Ключевые слова: miR-1322, mRNA, ген, полиглутамин, заболевание

Information about authors:

Yurikova Oxana Yuryevna, PhD-student, research assistant; Scientific research institute of biology and biotechnology problems, al-Farabi Kazakh national university, Almaty, Kazakhstan; oksanayurikova@mail.ru; <https://orcid.org/0000-0001-7442-0743>

Atambayeva Shara Alpysbayevna, candidate of biological sciences, associate professor, lead researcher; Scientific research institute of biology and biotechnology problems, al-Farabi Kazakh national university, Almaty, Kazakhstan; atambayevashara@gmail.com; <https://orcid.org/0000-0001-7189-3115>

Bolshoy Alexander, PhD, associate professor, Department of Evolutionary and Environmental Biology, University of Haifa, Israel, Haifa; bolshoy@research.haifa.ac.il; <https://orcid.org/0000-0002-8516-0649>

Ivashchenko Anatoliy Timofeevich, doctor of biological sciences, professor, chief researcher; Scientific research institute of biology and biotechnology problems, al-Farabi Kazakh national university, Almaty, Kazakhstan; a_ivashchenko@mail.ru; <https://orcid.org/0000-0002-7969-2016>

REFERENCES

- [1] Lytle J.R., Yario T.A., Steitz J.A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5'UTR as in the 3' UTR // *Proc. Natl. Acad. Sci USA*. 2007. Vol. 104, N 23. P. 9667-9672. DOI:10.1073/pnas.0703820104.
- [2] Tay Y., Zhang J., Thomson A.M., Lim B., Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation // *Nature*. 2008. Vol. 455. P. 1124-1128. DOI:10.1038/nature07299
- [3] Ivashchenko A., Berillo O., Pyrkova A., Niyazova R., Atambayeva S. MiR-3960 binding sites with mRNA of human genes // *Bioinformatics*. 2014. Vol. 10, N. 7. P. 423-427. doi:10.6026/97320630010423
- [4] Schnall-Levin M., Rissland O.S., Johnston W.K., Perrimon N., Bartel D.P., Berger B. Unusually effective microRNA targeting within repeat-rich coding regions of mammalian mRNAs // *Genome Res*. 2011. Vol. 21, N 9. P. 1395-1403. doi:10.1101/gr.121210.111
- [5] Imanbayeva A.A., Belozarov I.F., Ishmuratova M.Yu. Using of computer programm «bd-plant-kz» for cadastral registration of plants of the natural flora of Kazakhstan // *News of the National academy of sciences of the Republic of Kazakhstan. Series of biological and medical*. 2018. Vol. 6, N 330. P. 20-29. <https://doi.org/10.32014/2018.2518-1629.13>
- [6] Aisina D.E., Ivashchenko A.T., Niyazova R.E., Atambayeva Sh.A. Characteristics of interaction of miRNA with mRNA of genes of E2F transcription factors family // *News of the National academy of sciences of the Republic of Kazakhstan. Series of biological and medical*. 2017. Vol. 2, N 320. P. 131-137.

- [7] Niyazova R., Berillo O., Atambayeva Sh., Pyrkova A., Alybayeva A., Ivashchenko A. miR-1322 binding sites in paralogous and orthologous gene // *BioMed Res.Int.* 2015. Vol. 2015. 7 p. <https://doi.org/10.1155/2015/962637>.
- [8] Keo A., Aziz N.A., Dzyubachyk O., van der Grond J., van Roon-Mom W.M.C., Lelieveldt B.P.F., Reinders M.J.T., Mahfouz A. Co-expression Patterns between ATN1 and ATXN2 Coincide with Brain Regions Affected in Huntington's Disease // *Front Mol Neurosci.* 2017. 10:399. doi: 10.3389/fnmol.2017.00399.
- [9] Yao J.L., Zhou Y.F., Yang X.J., Qian X.D., Jiang W.P. KCNN3 SNP rs13376333 on chromosome 1q21 confers increased risk of atrial fibrillation // *Int Heart J.* 2015. Vol. 56. P. 511-515. DOI:10.1536/ihj.15-133
- [10] Dolga A.M. et al. Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons // *Cell Death Dis.* 2014. doi: 10.1038/cddis.2013.530
- [11] González P., García-Castro M., Reguero J.R., Batalla A., Ordoñez A.G., Palop R.L., Lozano I., Montes M., Alvarez V., Coto E. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction // *J Med Genet.* 2006. Vol 43. P. 167-169. doi: 10.1136/jmg.2005.035071
- [12] Zhang L., Sun Y., Fei M., Tan C., Wu J., Zheng J., Tang J., Sun W., Lv Z., Bao J., Xu Q, Yu H. Disruption of chaperone-mediated autophagy-dependent degradation of MEF2A by oxidative stress-induced lysosome destabilization // *Autophagy.* 2014. Vol. 10, N 6. P. 1015-1035. DOI:10.4161/auto.28477
- [13] Singh B., Owens K.M., Bajpai P., et al. Mitochondrial DNA Polymerase POLG1 Disease Mutations and Germline Variants Promote Tumorigenic Properties // *PLoS One.* 2015. Vol. 10, N 10. DOI:10.1371/journal.pone.0139846
- [14] Ylönen S., Ylikotila P., Siitonen A., Finnilä S., Autere J., Majamaa K. Variations of mitochondrial DNA polymerase γ in patients with Parkinson's disease // *J Neurol.* 2013. Vol. 260, N 12. P. 3144-3149. DOI:10.1007/s00415-013-7132-7
- [15] Orr H.T., Chung M.Y., Banfi S., Kwiatkowski T.J.Jr., Servadio A., Beaudet A.L., McCall A.E., Duvick L.A., Ranum L.P., Zoghbi H.Y. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1 // *Nat. Genet.* 1993. Vol. 4. P. 221-226.
- [16] Fournier C., Anquetil V., Camuzat A., et al. Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias // *Acta Neuropathol Commun.* 2018. Vol. 6, N 41. doi:10.1186/s40478-018-0547-8
- [17] Sopher B.L., Ladd P.D., Pineda V.V., et al. CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA // *Neuron.* 2011. Vol. 70, N 6. P. 1071-1084. doi:10.1016/j.neuron.2011.05.027
- [18] La Spada A.R., Taylor J.P. Repeat expansion disease: progress and puzzles in disease pathogenesis // *Nat Rev Genet.* 2010. Vol. 11, N 4. P. 247-258. doi:10.1038/nrg2748
- [19] Yao J.L., Zhou Y.F., Yang X.J., Qian X.D., Jiang W.P. KCNN3 SNP rs13376333 on chromosome 1q21 confers increased risk of atrial fibrillation // *Int. Heart J.* 2015. Vol. 56, N. 5. P. 511-515. doi: 10.1536/ihj.15-133
- [20] Zhang L., Sun Y., Fei M, et al. Disruption of chaperone-mediated autophagy-dependent degradation of MEF2A by oxidative stress-induced lysosome destabilization // *Autophagy.* 2014. Vol. 10, N 6. P. 1015-1035. doi:10.4161/auto.28477
- [21] Wang Q. Molecular genetics of coronary artery disease // *Curr Opin Cardiol.* 2005. Vol. 20, N 3. P. 182-188. PMID: 15861005
- [22] Bai X., Wu L., Liang T., Liu Z., Li J., Li D., Xie H., Yin S., Yu J., Lin Q, Zheng S. Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma // *J Cancer Res Clin Oncol.* 2008. Vol. 134, N 1. P. 83-91. DOI:10.1007/s00432-007-0252-7

Publication Ethics and Publication Malpractice in the journals of the National Academy of Sciences of the Republic of Kazakhstan

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

Submission of an article to the National Academy of Sciences of the Republic of Kazakhstan implies that the described work has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. In particular, translations into English of papers already published in another language are not accepted.

No other forms of scientific misconduct are allowed, such as plagiarism, falsification, fraudulent data, incorrect interpretation of other works, incorrect citations, etc. The National Academy of Sciences of the Republic of Kazakhstan follows the Code of Conduct of the Committee on Publication Ethics (COPE), and follows the COPE Flowcharts for Resolving Cases of Suspected Misconduct (http://publicationethics.org/files/u2/New_Code.pdf). To verify originality, your article may be checked by the Cross Check originality detection service <http://www.elsevier.com/editors/plagdetect>.

The authors are obliged to participate in peer review process and be ready to provide corrections, clarifications, retractions and apologies when needed. All authors of a paper should have significantly contributed to the research.

The reviewers should provide objective judgments and should point out relevant published works which are not yet cited. Reviewed articles should be treated confidentially. The reviewers will be chosen in such a way that there is no conflict of interests with respect to the research, the authors and/or the research funders.

The editors have complete responsibility and authority to reject or accept a paper, and they will only accept a paper when reasonably certain. They will preserve anonymity of reviewers and promote publication of corrections, clarifications, retractions and apologies when needed. The acceptance of a paper automatically implies the copyright transfer to the National Academy of Sciences of the Republic of Kazakhstan.

The Editorial Board of the National Academy of Sciences of the Republic of Kazakhstan will monitor and safeguard publishing ethics.

Правила оформления статьи для публикации в журнале смотреть на сайте:

www.nauka-nanrk.kz

ISSN 2518-1629 (Online), ISSN 2224-5308 (Print)

<http://biological-medical.kz/index.php/en/>

Редактор *М. С. Ахметова, Т. М. Апендиев, Д. С. Аленов*
Верстка на компьютере *Д. Н. Калкабековой*

Подписано в печать 26.07.2019.

Формат 60x881/8. Бумага офсетная. Печать – ризограф.
4,2 п.л. Тираж 300. Заказ 4.